U.S. Government Secures 3.2 Million Doses of Novavax COVID-19 Vaccine

GAITHERSBURG, Md.July 11, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced an agreement with the U.S. Department of Health and Human Services (HHS), in collaboration with the Department of Defense, to secure an initial 3.2 million doses of Novavax' COVID-19 vaccine (NVX-CoV2373) should it receive U.S. Food and Drug Administration (FDA) Emergency Use Authorization (EUA) and a recommendation from the Centers for Disease Control and Prevention (CDC). Novavax' protein-based vaccine will be made available for free to states, jurisdictions, federal pharmacy partners, and federally qualified health centers.


Continue Reading Here


Additional Info

Media Contact : Ali Chartan

Powered By GrowthZone

LEARN ABOUT MEMBERSHIP

LOG IN TO ACCESS
MEMBER TO MEMBER DISCOUNTS